<DOC>
	<DOCNO>NCT00000969</DOCNO>
	<brief_summary>To evaluate compare effectiveness toxicity associate didanosine ( ddI ) zalcitabine ( dideoxycytidine ; ddC ) patient HIV infection intolerant fail zidovudine ( AZT ) therapy . Alternative less toxic treatment need investigate treatment HIV infection . Studies show dideoxynucleosides ddI ddC may effective antiretroviral agent treatment HIV-infected individual . However , ddI ddC yet compare basis patient survival , drug tolerance , immunologic virologic effectiveness , incidence opportunistic infection opportunistic malignancy . Results study yield information regard relative therapeutic benefit toxicity drug provide alternative treatment patient unable tolerate progression disease AZT .</brief_summary>
	<brief_title>A Prospective , Randomized , Open-Label , Comparative Trial Dideoxyinosine ( ddI ) Versus Dideoxycytidine ( ddC ) HIV-Infected Patients Who Are Intolerant Who Have Failed Zidovudine ( AZT ) Therapy</brief_title>
	<detailed_description>Alternative le toxic treatment need investigate treatment HIV infection . Studies show dideoxynucleosides ddI ddC may effective antiretroviral agent treatment HIV-infected individual . However , ddI ddC yet compare basis patient survival , drug tolerance , immunologic virologic effectiveness , incidence opportunistic infection opportunistic malignancy . Results study yield information regard relative therapeutic benefit toxicity drug provide alternative treatment patient unable tolerate progression disease AZT . After baseline screening , patient randomize one two treatment arm ( ddI ddC ) . Subjects evaluate biweekly first 4 week study , 2 month , every month thereafter . Three dose level ddI ( base patient 's weight study entry ) compare two dose level ddC ( also base patient weight ) . Patients reach new progression-of-disease primary endpoint least 12 week treatment drug intolerance endpoint option switch alternate study drug ; however , participant encourage remain original drug assignment whenever possible . For switchover , patient must originally assign drug least 72 hour switch . Only one switchover allow .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Acyclovir ( patient also receive ddC , clinical monitoring frequent ) . Analgesics , antiemetic , antidiarrheal agent , necessary treatment symptomatic therapy . Interferons maintenance therapy Kaposi 's sarcoma . GMCSF . Required : Prophylaxis Pneumocystis carinii pneumonia ( PCP ) absolute CD4+ lymphocyte count &lt; 200 cells/mm3 study entry . PCP prophylaxis patient CD4+ count 200 300 cells/mm3 discretion patient 's primary physician . NOTE : There potential interaction ddI dapsone . Concurrent Treatment : Allowed : Transfusion , erythropoietin . Patients must follow : Zidovudine ( AZT ) failure receive cumulative duration least 6 month . AZT intolerance rechallenge require patient exhibit = &gt; grade III cutaneous symptom . Diagnosis AIDS CD4+ = &lt; 300 cells/mm3 OR AIDSdefining illness Kaposi 's sarcoma . Willingness ability comply protocol . Informed consent must obtain study participant accordance state law , local IRB requirement , 45 CFR Part 46 . AMENDED 11/19/90 include assent minor physically able , addition consent parent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Any disorder study drug contraindicate ( didanosine ( ddI ) ) contraindicate renal impairment , heart disease , receive renal dialysis . Active opportunistic infection . Concurrent Medication : Excluded : Other antiretroviral agent . Use drug associate peripheral neuropathy use agent may cause pancreatitis include intravenous pentamidine alcohol restrict avoided . Concurrent Treatment : Excluded : Other concurrent antiretroviral clinical trial . Patients follow excluded : History pancreatitis , peripheral neuropathy , uncontrolled seizure , renal impairment , heart disease , stage 2 high ADC . Any disorder study drug contraindicate , i.e. , ddI contraindicate renal impairment , patient receive renal dialysis , heart disease . Receiving acute therapy active AIDS defining opportunistic infection enrollment . Prior Medication : Excluded : Didanosine ( ddI ) . Dideoxycytidine ( ddC ) . Excessive alcohol use , investigator 's opinion , put patient risk develop pancreatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Zidovudine</keyword>
</DOC>